Associate Scientist - Functional Service Provider
About the job
- Basic knowledge in protein chemistry and bioprocessing.
- Basic knowledge and preferably hands-on experience with column and membrane chromatography, including affinity, size exclusion, ion exchange, and multi-mode chromatography, as well as filtration technology.
- A bachelor's degree in Chemical Engineering, Biomedical Engineering, Biological Sciences, or another related degree concentration, or equivalent directly related experience.
- Ability to work weekends and overnight hours as needed.
- Perform or aid in purification process development, optimization, and scale-up manufacturing.
- Conduct protein purification to support the formulation team's material needs and cell culture development.
- Perform routine analyses of in-process samples using relevant product-purity and process-impurity analytical tools.
- Prepare buffers and solutions needed for laboratory work.
- Present work summaries in a weekly group meeting.
- Write routine electronic laboratory notebook entries.
- Perform other responsibilities as assigned.
- Experience in protein analysis, including high-performance liquid chromatography, enzyme-linked immunosorbent assay, pH, conductivity, and A280 concentration testing.
- Hands-on experience or basic knowledge of ultrafiltration/diafiltration experimentation and tangential flow filtration systems.
- Inventory management skills.
- Good verbal and written communication skills.
About the company
Thermo Fisher Scientific supplies labs, hospitals, and biotech firms with a broad range of products and services, from basic lab consumables to advanced analytical instruments and outsourced drug development. Its offerings work by combining high-tech instruments for genomics, diagnostics, and research with consumables and a global distribution network to deliver end-to-end workflows that turn samples into data and insights. The company differentiates itself through its massive, diversified portfolio and its integrated end-to-end reach—from tools and reagents to support services—built on the legacy of Fisher Scientific’s distribution strength and Thermo Electron’s instrument innovation, backed by a history of strategic acquisitions. The goal is to be the dominant partner in science and healthcare by enabling researchers and clinicians to perform work more efficiently and at larger scale, spanning discovery, development, and manufacturing.
Company Size
10,001+
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
1956
Get referred to Thermo Fisher Scientific
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10% to $11.99 billion, with 13% adjusted EPS growth.
- May 2026 Precure with Mayo Clinic targets a million-biospecimen dataset and proteomics leadership.
- June 2026 NVIDIA, September 2026 Evosep, and CHO-K1 launches widen Thermo Fisher’s platform pull.
What critics are saying
- Organic revenue grew only 1% in Q1 2026, exposing acquisition dependence.
- The August 2026 microbiology sale removed $645 million revenue and cut Specialty Diagnostics depth.
- Clario’s $8.875 billion deal needs $175 million synergies; failure damages 2027 earnings credibility.
What makes Thermo Fisher Scientific unique
- Thermo Fisher spans consumables, instruments, services, and trial data across every lab workflow.
- March 2026 Clario added endpoint-data infrastructure, linking instruments to clinical-trial evidence generation.
- Thermo Fisher’s 2026 launches, from CHO-K1 media to Multiskan Ease, cover routine lab demand.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Fertility Treatment Support
Family Planning Benefits
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Company News
Evosep has entered a reseller agreement with Thermo Fisher Scientific for its Evosep Eno separation platform. Through the partnership, Thermo Fisher Scientific will offer the platform as part of its mass spectrometry solutions portfolio, combining its global reach with Evosep's separation technology. The Evosep Eno platform addresses the need for standardised proteomics in research, drug discovery, and clinical applications. It delivers robustness, ease of use, and throughput whilst minimising operational complexity. Customers will be able to purchase Evosep Eno directly through Thermo Fisher Scientific. The platform enables standardised separations across laboratories, instruments, and operators, supporting reproducible results for large-scale studies. The agreement supports applications including population studies, biomarker discovery, drug development, and clinical proteomics initiatives.
AI accelerator cards reshape DNA sequencing workflows. The global market for AI DNA sequencer base-calling accelerator cards is expanding as genomics workflows require faster, more accurate nucleotide identification. These specialized compute modules offload signal processing and deep-learning inference from host CPUs, reducing data-transfer bottlenecks and enabling on-instrument analytics that once depended on large data-center environments. Growth is tied to rising sequencing demand, with sequencing expenditures projected to surpass US$ 30 billion annually. Long-read and single-cell applications are increasing the need for flexible AI-optimized compute, while clinical diagnostics, research and development, and personalized medicine are key application areas. On-premise integration, cloud-connected systems, and hybrid edge deployments are shaping adoption models. NVIDIA, Intel, Illumina, and Thermo Fisher Scientific lead the competitive field through GPU, ASIC, FPGA, and platform-specific approaches. Illumina has introduced the NovaBase AI card, while Thermo Fisher Scientific offers the Ion Torrent Accelerate Card. AMD, Xilinx, Hewlett Packard Enterprise, Cisco, Qualcomm, IBM, Pacific Biosciences, Oxford Nanopore Technologies, Roche Sequencing Solutions, BGI Genomics, and QIAGEN are pursuing specialized roles across the ecosystem. Europe is positioned as a highly advanced market due to strong research networks, privacy regulation, and sustainability priorities. North America benefits from federal research funding and biotech activity, while Asia-Pacific shows strong potential through expanding genomics infrastructure in China, Japan, South Korea, and India.
Thermo Fisher Scientific inc. launches Gibco? CHO-K1 Catalog Panel media and feed. Published on 09/23/2026 at 11:43 am EDT S&P Capital IQ Thermo Fisher Scientific announced the Gibco? CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell lines. Available in liquid and dry powder media (DPM) formats, the panel can offer flexible options for process development, scale-up, and manufacturing. The panel consists of multiple basal media and feed combinations designed for a broad range of CHO-K1 cell lines, helping development teams rapidly identify medium and feed combinations that support higher performance. The chemically defined (CD), animal origin-free (AOF) formulations are cGMP-ready to support regulatory considerations. The Gibco CHO-K1 Catalog Panel helps upstream process development teams identify high-performing media and feed combinations. In a 14-day fed-batch study using a CHO-K1 GS cell line, select panel combinations demonstrated: · Up to 73% higher titer compared with the benchmark catalog media and feeds tested · Up to 202% higher peak viable cell density compared with the benchmark products tested · Strong product quality performance across tested conditions A cGMP-ready portfolio of basal and feed media for CHO-K1 cell culture and protein production. Biologics and biosimilars developers using CHO-K1 cell lines. It helps provide multiple ready-to-use media and feed options for evaluating and optimizing diverse CHO-K1 cell culture workflows. The panel combines demonstrated productivity and product quality performance with CD, AOF, cGMP-ready formulations and scalable liquid and DPM formats to support CHO-K1 process development through manufacturing. (C) S&P Capital IQ - Business Wire - 2026
Nuclera appoints Carl Raimond as Chief Executive Officer. * Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific * Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer Cambridge, UK, and Boston, MA, USA, 22 September 2026: Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the appointment of Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera's co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships. The leadership transition marks the next phase in Nuclera's evolution as the Company builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. The combination of Carl's experience scaling life-science businesses with Michael's scientific leadership and deep understanding of Nuclera's technology and markets will support the Company as it expands adoption of its platform across priority life-science workflows. Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate the speed of protein science, with current focus areas including full-length IgG antibody screening, challenging membrane protein synthesis, and soluble protein expression. In May 2026, the Company launched antibody service capabilities to support early experimental triage for antibody discovery programs, complementing its eProtein Discovery(TM) system for in-house protein expression and screening. The Company is also extending its antibody strategy beyond centralized service delivery. Nuclera is advancing early partner work toward customer-site antibody screening workflows, designed to bring cell-free expression and binding triage closer to AI-enabled discovery teams and reduce the delay between computational design and experimental evidence. Carl joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. An experienced life-sciences executive, Carl has also held senior leadership roles at PerkinElmer, Agilent Technologies and Affymetrix. As Chief Scientific and Business Officer, Michael will focus on scientific strategy, market development and strategic partnerships, working closely with Carl as the Company enters its next phase of growth whilst maintaining continuity in Nuclera's scientific direction. Carl Raimond, CEO at Nuclera, said: "Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I'm excited to join the Company as we sharpen our focus on customer adoption, commercial execution, and expanding applications of our technology across life-science workflows. Michael's scientific leadership remains central to Nuclera's future, and I look forward to working with him and the team to translate this strong technology foundation into impactful solutions for our customers." Dr Michael Chen, co-founder and Chief Scientific and Business Officer at Nuclera, commented: "As a structural biologist, I know firsthand the time and frustration protein production can cost a development program. That frustration is part of why we started Nuclera. I'm incredibly proud of what the team has built and the difference our technology is already making for protein scientists. Now, we've reached an important point in the Company's evolution, and Carl is the right CEO to lead us forward. Carl's experience building and scaling life-science businesses, combined with his understanding of the opportunity ahead, will be a huge asset to Nuclera. I'm excited to work alongside him to bring that impact to every benchtop."
Nuclera appoints ex-Thermo Fisher exec Carl Raimond as CEO. Business Weekly 22 Sep 2026 Cambridge biotech company Nuclera has appointed Carl Raimond as CEO in a move that sees co-founder Dr Michael Chen transition to the role of Chief Scientific and Business Officer. The company says the leadership change marks the next phase in Nuclera's evolution as it builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. Raimond joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. As Chief Scientific and Business Officer, Dr Michael Chen will focus on scientific strategy, market development and strategic partnerships. Raimond said: "Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I'm excited to join the Company as Cambridge Innovation Capital plc sharpen its focus on customer adoption, commercial execution, and expanding applications of its technology across life-science workflows. "Michael's scientific leadership remains central to Nuclera's future, and I look forward to working with him and the team to translate this strong technology foundation into impactful solutions for our customers." Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate the speed of protein science, with current focus areas including full-length IgG antibody screening, challenging membrane protein synthesis, and soluble protein expression. In May 2026, the Company launched antibody service capabilities to support early experimental triage for antibody discovery programs, complementing its eProtein Discovery(TM) system for in-house protein expression and screening. The Company is also extending its antibody strategy beyond centralised service delivery. Nuclera is advancing early partner work toward customer-site antibody screening workflows, designed to bring cell-free expression and binding triage closer to AI-enabled discovery teams and reduce the delay between computational design and experimental evidence. Dr Chen said: "As a structural biologist, I know firsthand the time and frustration protein production can cost a development program. That frustration is part of why Cambridge Innovation Capital plc started Nuclera. I'm incredibly proud of what the team has built and the difference its technology is already making for protein scientists. "Now, we've reached an important point in the Company's evolution, and Carl is the right CEO to lead us forward. Carl's experience building and scaling life-science businesses, combined with his understanding of the opportunity ahead, will be a huge asset to Nuclera. I'm excited to work alongside him to bring that impact to every benchtop."